• Founded: 2016
  • Location: Rochester, MN
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Multiple cancers
  • Drug types: ONC
  • Lead product: Voyager-V1
  • Product link: https://vyriad.com/clinical-program/
  • Funding: $29.5M B May 2022; $24M B Nov 2019



job board

Short description:


Drug notes:

Also Clin2 NSCLC, head & neck cancer, 2 combo trials Clin1 multiple cancers, mono Clin1 solid tumors; MV-NIS Clin1 bladder cancer, Clin1 medulloblastoma, ATRT

Long description:

Vyriad is using a cross-functional approach to develop the next generation of gene therapies and oncolytic virotherapies. Their scientific focus revolves around engineering viral vectors and viruses to selectively infect and destroy cancer cells while sparing healthy tissues. Their approach uses cell-specific targeting, efficiency and stability for targeted genetic medicines. They have optimized engineered G proteins for their lentiviral vectors to accomplish long-term durability. By harnessing the natural ability of viruses to target and eliminate cancer cells, Vyriad aims to develop innovative treatments for challenging cancers. Their approach represents a frontier in cancer therapy, leveraging cutting-edge science to advance personalized medicine solutions for oncology and immunology.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com